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A paper from Jain et al. (2016) using whole-genome CRISPR knockout libraries in human cells and models of
mitochondrial disease suggests chronic hypoxia could be an unexpected treatment for disorders of mito-
chondrial respiration.Mitochondria are responsible for the
production of 90% of cellular ATP during
oxidative phosphorylation (OXPHOS), a
process that couples cellular respiration
to ATP production. Specifically, elec-
trons are transferred from NADH or
FADH2 via multi-subunit respiratory
chain complexes and carriers to molecu-
lar oxygen, with the concomitant proton
electrochemical gradient being har-
nessed by a fifth complex, the FoF1
ATP synthase, to form ATP. Defects in
the mitochondrial respiratory chain (RC)
underlie many inherited mitochondrial
disorders and have been implicated in
multiple neurological and metabolic dis-
eases. The development of treatments
for mitochondrial dysfunction has been
the focus of intensive research across
multiple labs; however, effective treat-
ments have proved to be elusive.
Several strategies for treatment devel-
opment are currently being followed
(Lightowlers et al., 2015). The majority
of these involve increasing the produc-
tion of ATP by the RC, either by
providing more substrate for OXPHOS
in the form of NADH precursors (Khan
et al., 2014), increasing mitochondrial
biogenesis to add to the pool of mito-
chondria available for ATP production
(Viscomi et al., 2011), targeting dysfunc-
tional mitochondria for degradation via
mitophagy (Villanueva Paz et al., 2016),
or degrading mitochondrial genomes
harboring disease-causing mutations
(Bacman et al., 2013; Gammage et al.,
2014) and thus improving mitochondrial
health. Recent work by Jain and col-
leagues in the Mootha laboratory has
now highlighted a new paradigm in treat-
ing mitochondrial diseases (Jain et al.,
2016).This is an oUsinga large-scaleCRISPRCas9-medi-
ated whole-genome knockout screen, the
authors were able to identify a set of
genes whose ablation improved survival
in cells with pharmacologically impaired
RC complex III. Surprisingly, the most
effective genetic suppressor of mito-
chondrial disease was inhibition of Von
Hippel-Lindau (VHL) factor, a key regu-
lator in the hypoxia response pathway
and recognized tumor suppressor pro-
tein. Under physiologically normoxic
conditions, a group of hypoxia-inducible
transcription factors (HIFs) are produced
and are hydroxylated, signaling them
for ubiquitination and subsequent degra-
dation by the VCB-Cull2 complex. VHL,
a core component of this complex, is
the E3 ubiquitin ligase. Under hypoxic
conditions, this hydroxylation step does
not occur, thus preventing degradation
of HIFs and allowing cells to respond in
environments with low oxygen tension.
The authors also show that VHL
knockout cells are resistant to other in-
hibitors of OXPHOS (RC complex I and
FoF1 ATP-synthase). Further, by using
a small-molecule inhibitor (FG-4592) of
the HIF hydroxylating enzyme prolyl-
hydroxylase, Jain et al. rescued a growth
defect in cell lines with Complex I, III,
or V inhibition.
These are intriguing observations, so
could hypoxia, counter-intuitively, help
whole organisms that suffer from an RC
defect? Strikingly, it appears so. Jain
et al. demonstrate that a mildly hypoxic
environment (11% O2) improves lifespan
in the Ndufs4 mouse model of Leigh’s
syndrome, the rare and fatal pediatric
mitochondrial disease that is simulated
in mice by the loss of a component of
RC complex I. Under normoxic (21%Molecular
pen access article under the CC BY license (hO2) conditions, these mice die after
60 days. Under hypoxic conditions,
HIF was stabilized in the mice and
caused transcription of hypoxic factors
including erythropoietin, a well-estab-
lished marker for hypoxia. Several indica-
tors of disease progression, such as
maintenance of body weight and temper-
ature, were improved, along with a dra-
matic restoration of their locomotor func-
tion. Conversely, survival was severely
impaired by hyperoxic conditions (55%
O2), with mice dying after a few days of
exposure to this condition.
The authors postulate that several
mechanisms may be acting to improve
the lifespan of the mice. First, the reduc-
tion in O2 tension could be decreasing
the production of reactive oxygen spe-
cies (ROS), which have been implicated
in the pathogenesis of mitochondrial
dysfunction (Hayashi and Cortopassi,
2015). Second, hypoxia may be acti-
vating HIFs, which will lessen the produc-
tion of ATP by OXPHOS via a reduced
supply of carbon to the TCA cycle and
increase the reliance on glycolysis
(Kim et al., 2006) (Figure 1). Indeed,
the authors show that several key
glycolytic enzymes are increased in
response to hypoxia. It is interesting to
note that work from Johnson et al.
(Johnson et al., 2013) appears to
contradict this finding. Although their
study showed that treatment of a
similar Ndufs4 KO model with tacrolimus,
the mTOR inhibitor, also improved the
phenotype, it was suggested that this
was due to metabolic remodeling lead-
ing to a decrease in glycolytic intermedi-
ates. These two contrasting findings will
need further investigation; however, it
could indicate that the reduction in ROSCell 62, April 7, 2016 ª2016 The Authors 5
ttp://creativecommons.org/licenses/by/4.0/).
Figure 1. Proposed Mechanism of Hypoxic
Treatment for Mitochondrial Disease
Stabilization of HIF, either by decreased oxygen
tension or small-molecule inhibitors of HIF degra-
dation, enables HIF translocation to the nucleus.
Stabilized HIF, in conjunction with its b subunit
ARNT and transcriptional coactivator p300, begins
a program of gene transcription causing increased
glycolysis, decreased OXPHOS, and, conse-
quently, a decline in ROS production, which is also
directly lowered by low O2 tension. These factors
combinedmay be protective against RC deficiency
in mitochondrial disease.
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Previewsduring hypoxia could be the key factor
in the improvements described, rather
than the promotion of glycolytic ATP
production.6 Molecular Cell 62, April 7, 2016As Jain et al. point out, prior to use as
a treatment, the relationship between
ROS availability, mitochondrial respira-
tion, and the physiological changes at
the organ level need to be deciphered.
Although the authors used FG-4592 to
induce the hypoxia response in cell lines
and zebrafish models, the high con-
centration (50 mM) and the imperme-
ability to the blood-brain barrier means
that other small molecules will have
to be developed to replicate hypoxia
in the central nervous system, the pri-
mary system affected by mitochondrial
disease. One safety issue that may also
need to be explored if considering
treatment is that, although the triggering
of the hypoxia response appears to
ameliorate the RC disorders, stability of
certain HIFs can be tumorigenic, consis-
tent with the role of VHL as a tumor
suppressor.
Although healthy humans can acclima-
tize to living in low-oxygen environments
such as the high Andes, the ability of
mitochondrial disease patients to adapt
to these conditions is unknown. This
might be particularly true for patients
who already have symptoms rather
than those who adapt before symptoms
develop. Patients with Leigh’s syn-
drome are often hypoxic due to hypoven-
tilation or infection, and whilst hyperoxia
is harmful in the Ndufs4 mice, careful
monitoring of oxygen tension in patients
is crucial during acute relapses. As the
authors state, further work is needed to
understand the effect of hypoxic condi-
tions between 11% and 20% O2 and
intermittent hypoxic treatment, as these
may be better tolerated. Clearly there
are many issues that need to be ad-
dressed; however, this work is exciting
and could open up a new and unex-pected front in the battle against mito-
chondrial disease.
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